PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript

Dikla Akselbrad: Again, I’ll start with the latter part of your question. Our top priority right now is, obviously, D-PLEX100, but we are fully intending to continue the development of OncoPLEX and potentially also other products in our pipeline and it’s remained a priority. What we have done up until now is developing the CMC processes. And as we continue our effort to begin clinical development, this will be a very valuable asset to get to this stage. I think another thing that is quite in a good stage is the preclinical package. Obviously, we will need a decent study to go into the clinical stage. But this is a priority. But you’re right, as I said before, our focus is on D-PLEX100, so obviously, the resources that are invested in OncoPLEX in the near terms are limited.

Ori Warshavsky: Yes. And I can add on the D-PLEX partnerships. All of the conversations that we had in the past, we’re still in contact with all of these potential partners. There’s actually a few new ones from other geographies that showed interest in partnering for different territories. So this is all ongoing. Obviously, a lot of it will depend on the trial, but no one really stepped back and lost interest in the product.

Dikla Akselbrad: I would add to that one thing, which is — the new thing that we are seeing with the robust data, the robust clinical data that we have from SHIELD I is a better understanding and some additional interest around our platform, around collaborating, around the PLEX platform pairing it with novel or known molecules in different areas, and this is very encouraging for us.

Operator: There are currently no further questions. I will hand the call back to you.

Dikla Akselbrad: Thank you for joining PolyPid’s Fourth Quarter and Year-End 2022 Financial Results Conference Call. I would like to emphasize our firmly, we continue to believe in our long-term prospects, especially the potential of our promising late-stage product candidate D-PLEX100. We remain grateful to our team members and all of our external partners for their commitment to our mission and their support in continuing to advance towards achieving our goal of bringing D-PLEX100 to health care providers and patients as quickly as possible. We look forward to speaking with you again on our next call.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.